Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVO
Alvotech
$9.19
+2.9%
$9.68
$7.35
$13.70
$2.77B0.11144,580 shs202,737 shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$29.88
+1.5%
$31.21
$24.10
$62.53
$2.79B0.25819,345 shs461,098 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$16.80
0.0%
$15.33
$12.72
$34.47
$2.90B0.631.22 million shs511,903 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$5.49
+1.1%
$5.20
$4.32
$14.45
$747.87M1.221.36 million shs395,502 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVO
Alvotech
0.00%+0.55%-12.48%+8.12%-24.36%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
0.00%-0.28%-7.56%+11.10%-32.41%
Immunovant, Inc. stock logo
IMVT
Immunovant
0.00%+4.37%+4.89%+15.25%-35.86%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
0.00%+6.19%+6.60%-1.61%-37.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alvotech stock logo
ALVO
Alvotech
3.5293 of 5 stars
3.54.00.00.03.30.01.9
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.3039 of 5 stars
3.50.00.03.71.12.50.0
Immunovant, Inc. stock logo
IMVT
Immunovant
1.4067 of 5 stars
3.52.00.00.00.01.70.0
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
3.2095 of 5 stars
3.42.00.00.02.13.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVO
Alvotech
3.00
Buy$18.0095.87% Upside
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.90
Moderate Buy$71.75140.17% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.90
Moderate Buy$38.33128.12% Upside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.86
Moderate Buy$32.86498.49% Upside

Current Analyst Ratings Breakdown

Latest VIR, ALVO, IMVT, and CRNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
5/22/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/12/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $14.00
4/22/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00
4/17/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $21.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVO
Alvotech
$491.98M5.63N/AN/A($1.37) per share-6.71
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$1.04M2,689.61N/AN/A$14.29 per share2.09
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.16 per shareN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$74.21M10.23N/AN/A$8.35 per share0.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVO
Alvotech
-$231.86M$0.3724.8445.95N/A16.42%-36.37%12.70%8/21/2025 (Estimated)
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$521.96M-$4.22N/AN/AN/A-2,769.04%-47.46%-39.33%7/30/2025 (Estimated)

Latest VIR, ALVO, IMVT, and CRNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.72-$0.64+$0.08-$0.64N/A$0.16 million
5/8/2025Q1 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million
5/7/2025Q1 2025
Alvotech stock logo
ALVO
Alvotech
-$0.17$0.35+$0.52$0.35N/AN/A
5/7/2025Q1 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVO
Alvotech
N/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alvotech stock logo
ALVO
Alvotech
N/A
1.73
1.19
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
22.53
22.53
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
11.16
11.16
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
6.79
6.79

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVO
Alvotech
N/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVO
Alvotech
N/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
6.00%
Immunovant, Inc. stock logo
IMVT
Immunovant
5.90%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVO
Alvotech
1,032301.48 millionN/ANot Optionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
21093.63 million88.01 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120170.92 million160.84 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
580138.24 million116.12 millionOptionable

Recent News About These Companies

Q1 2025 Vir Biotechnology Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alvotech stock logo

Alvotech NASDAQ:ALVO

$9.19 +0.26 (+2.91%)
As of 07/3/2025 02:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$29.88 +0.44 (+1.48%)
Closing price 07/3/2025 01:45 PM Eastern
Extended Trading
$30.20 +0.32 (+1.07%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$16.80 -0.01 (-0.04%)
Closing price 07/3/2025 02:41 PM Eastern
Extended Trading
$16.80 +0.00 (+0.01%)
As of 07/3/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$5.49 +0.06 (+1.10%)
Closing price 07/3/2025 03:36 PM Eastern
Extended Trading
$5.42 -0.07 (-1.18%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.